Effects of prolylendopeptidase inhibitor benzyloxycarbonyl-methionyl-2(S)-cyanopyrrolidine on experimental depressive syndrome development in rats

Bulletin of Experimental Biology and Medicine

Volumn 147, Issue 1, 2009, Pages 26-30

  Khlebnikova, N N ^a   Krupina, N A ^a   Bogdanova, N G ^a   Zolotov, N N ^a   Kryzhanovskii, G N ^a  

^a INSTITUTE OF GENERAL PATHOLOGY AND PATHOPHYSIOLOGY   (Russian Federation)

Author keywords

1 methyl 4 phenyl 1,2,3,6 tetrahydropyridine; Benzyloxycarbonyl methionyl 2(S) cyanopyrrolidine; Experimental depressive syndrome; Prolylendopeptidase inhibitor; Rats

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; BENZYLOXYCARBONYLMETHIONYL 2 CYANOPYRROLIDINE; NEUROTOXIN; PROLYL ENDOPEPTIDASE INHIBITOR; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; DRUG MECHANISM; ENZYME INHIBITION; HOPELESSNESS; MALE; NONHUMAN; RAT; STRESS; SWIMMING; SYMPTOMATOLOGY; SYSTEMIC THERAPY; THYMUS; WISTAR RAT;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; DEPRESSION; MALE; METHIONINE; PROTEASE INHIBITORS; PYRROLIDINES; RATS; RATS, WISTAR; SERINE ENDOPEPTIDASES;

RATTUS;

EID: 67649395491     PISSN: 00074888     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10517-009-0458-6     Document Type: Article

References (15)

1. T. A. Voronina and S. B. Seredenin, Eksper. Klin. Farmakol., 65, No. 5, 4-17 (2002).
2. N. N. Zolotov, V. B. Narkevich, A. V. Prikhozhan, et al., Dokl. AN, 322, No. 4, 624-626 (1992).
3. N. A. Krupina, N. N. Zolotov, N. G. Bogdanov, et al., Bull. Eksper. Biol. Med., 142, No. 11, 497-499 (2006).
4. N. A. Krupina and G. N. Kryzhanovskiy, Zh. Nevrol. Psikhiatr. No. 4, 42-47 (2003).
5. G. N. Kryzhanovskii, N. A. Krupina, and V. G. Kucheryanu, Zh. Vyssh. Nervn. Deyat., 45, No. 2, 377-387 (1995).
6. V. B. Narkevichm, G. A. Nazarova, N. N. Zolotov, et al., Dokl. AN, 339, No. 5, 691-693 (1994).
7. V. I. Rodina, N. A. Krupina, G. N. Kryzhanovskii, and N. B. Oknina, Byull. Eksp. Biol. Med, 114, No. 7, 11-14 (1992).
8. C. Belzung, L. Yalcin, G. Griebel, et al., CNS Neurol Disord Drug Targets, 5, No. 2, 135-145 (2006).
9. A. S. Elhwuegi, Prog. Neuropsychopharmacol. Biol. Psychiatry, 28, No. 3, 435-451 (2004).
10. A. Holmes, M. Heiling, N.M. Rupniak, et al., Trends. Pharmacol. Sci., 24, No. 11, 580-588 (2003).
11. M. Maes, F. Goossens, S. Scharpe, et al., Biol. Psychiatry, 35, No. 8, 545-552 (1994).
12. M. Maes, S. Bonaccorso, V. Marino, et al., Mol. Psychiatry, 6, No. 4, 475-480 (2001).
13. S. O. Reber, L. Birkeneder, A. H. Veenema, et al., Endocrinology, 148, No. 2, 670-682 (2006).
14. J. S. Schneider, M. Giardiniere, and P. Morain, Neuropsychopharmacology, 26, No. 2, 176-182 (2002).
15. Y. M. Ulrich-Lai, H. F. Figueiredo, M. M. Ostrander, et al., Am. J. Physiol. Endocrinol. Metab., 291, No. 5, E965-E973 (2006).